Van der Galien HT, Kooistra HA, Veeger NJGM, et al. Outcome of a 10-year population-based cohort of diffuse large B-cell lymphoma patients in the first-line, refractory and relapsed setting: ‘real world’ data identify subgroups in need of new therapies. EHA 2018; poster PF287.
Vraagstukken rond de financiële houdbaarheid van CAR T-celtherapie
feb 2024 | Immuuntherapie, Leukemie, Lymfoom